Plain-English translation of NCT06393816 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether durvalumab—a type of immunotherapy drug that helps your immune system fight cancer—works better when combined with two chemotherapy drugs (etoposide and either cisplatin or carboplatin) for treating advanced large-cell neuroendocrine carcinoma of the lung. Currently, patients with this rare cancer receive chemotherapy alone, which helps some people but stops working for many others. Researchers hope this medication combination will help more patients live longer.
Large-cell neuroendocrine carcinoma is a rare and aggressive lung cancer with poor outcomes—most patients survive only 8–10 months with current treatment. Recent studies suggest that adding immunotherapy to chemotherapy might significantly improve survival, so this trial is testing whether this medication combination can deliver better results.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combination as an outpatient, typically starting with chemotherapy and immunotherapy administered intravenously in cycles. You would visit the hospital or clinic regularly for treatment sessions, blood tests, and imaging scans to monitor how well the treatment is working and to check for side effects. The trial involves about 80 patients across multiple centers, and your participation would continue as long as the treatment is helping and you are tolerating it well.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
France